A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

Trial Profile

A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Girentuximab I-124 (Primary)
  • Indications Renal cell carcinoma
  • Focus Diagnostic use
  • Acronyms REDECT 2
  • Sponsors WILEX Inc
  • Most Recent Events

    • 20 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 20 Dec 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
    • 20 Dec 2017 Planned initiation date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top